Jim Kelly

Mr. Kelly is executive vice president, chief financial officer (CFO) and treasurer with responsibility for finance and information technology. He brings more than 25 years of industry experience in both commercial and clinical-stage companies to Novavax.

He joins Novavax from Supernus Pharmaceuticals, where he served as CFO. Previously, he spent 10 years at Vanda Pharmaceuticals, where he was CFO and treasurer from 2010-20. From 2000-10, Mr. Kelly served in finance roles of increasing responsibility at MedImmune (now AstraZeneca) and Biogen, most recently as the Vice President and Controller of MedImmune.

Mr. Kelly previously was a member of the corporate finance team at Aetna responsible for mergers and acquisitions and treasury management, and with Janssen, a division of Johnson & Johnson. He holds a Master of Business Administration from Cornell University, a Bachelor of Science in Business Administration from the University of Vermont and is a CFA charterholder.